<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Sandoz</title>
	<atom:link href="http://www.tapanray.in/tag/sandoz/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Focus On Core Competencies &#8211; Regardless of Generic Or Innovative Drug Business</title>
		<link>http://www.tapanray.in/focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business</link>
		<comments>http://www.tapanray.in/focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business/#comments</comments>
		<pubDate>Mon, 22 Feb 2021 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[antibiotics]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Carving-out]]></category>
		<category><![CDATA[cephalosporin]]></category>
		<category><![CDATA[cephalosporins]]></category>
		<category><![CDATA[competencies]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[Fortum]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regardless]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[shifting]]></category>
		<category><![CDATA[Spin-offs]]></category>
		<category><![CDATA[Splitting-off]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[strength]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Zinacef]]></category>
		<category><![CDATA[Zinnat]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10421</guid>
		<description><![CDATA[On February 11, 2021, by two different Press Releases, two global pharma majors – GSK and Novartis simultaneously made interesting announcements. Both were related to three generic cephalosporin antibiotics. GSK revealed, ‘it has reached an agreement with Sandoz &#8211; a &#8230; <a href="http://www.tapanray.in/focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Game is Changing: Ensure Better Treatment Outcomes: Leverage Technology</title>
		<link>http://www.tapanray.in/the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology</link>
		<comments>http://www.tapanray.in/the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology/#comments</comments>
		<pubDate>Mon, 03 Jun 2019 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[augmentation]]></category>
		<category><![CDATA[basic]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[Digihaler]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Disruptive]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[medication]]></category>
		<category><![CDATA[non-drug]]></category>
		<category><![CDATA[outcome]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[ProAir]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[replacement]]></category>
		<category><![CDATA[reSet]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[Therapeutics]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[types]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9570</guid>
		<description><![CDATA[Today, several pharma players, mostly ‘encouraged’ by many non-pharma tech companies, are trying to gain, at least, a toehold in the digital health care space. It is visible even within the generic drug industry. Such initiatives, as they gain a &#8230; <a href="http://www.tapanray.in/the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Prescription Digital Therapy Now A Reality</title>
		<link>http://www.tapanray.in/prescription-digital-therapy-now-a-reality/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=prescription-digital-therapy-now-a-reality</link>
		<comments>http://www.tapanray.in/prescription-digital-therapy-now-a-reality/#comments</comments>
		<pubDate>Mon, 07 May 2018 00:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2]]></category>
		<category><![CDATA[3]]></category>
		<category><![CDATA[app]]></category>
		<category><![CDATA[Apple]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[chronic]]></category>
		<category><![CDATA[cognition]]></category>
		<category><![CDATA[diabetic]]></category>
		<category><![CDATA[digiceuticals]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[disorder]]></category>
		<category><![CDATA[Epilepsy]]></category>
		<category><![CDATA[fitness]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MDD]]></category>
		<category><![CDATA[mood]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Parkinson's]]></category>
		<category><![CDATA[Pear]]></category>
		<category><![CDATA[Pears]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reality]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[reSet]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[scope]]></category>
		<category><![CDATA[seizures]]></category>
		<category><![CDATA[Substance]]></category>
		<category><![CDATA[Takeda]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Therapeutics]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[use]]></category>
		<category><![CDATA[version]]></category>
		<category><![CDATA[Watch]]></category>
		<category><![CDATA[wealthy]]></category>
		<category><![CDATA[wearable]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8981</guid>
		<description><![CDATA[The pursuit of offering ‘prescription digital therapeutics’ or ‘digiceuticals’ by Big Pharma, to ensure better clinical outcomes for patients, has apparently come to fruition now. On April 18, 2018, by a media release, Novartis announced that the Sandoz Division of the Company &#8230; <a href="http://www.tapanray.in/prescription-digital-therapy-now-a-reality/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/prescription-digital-therapy-now-a-reality/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biosimilar Drugs: Why Prescriptions Aren’t Still Enough?</title>
		<link>http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biosimilar-drugs-why-prescriptions-arent-still-enough</link>
		<comments>http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/#comments</comments>
		<pubDate>Mon, 14 Sep 2015 00:00:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[filgrastim]]></category>
		<category><![CDATA[filgrastim-sndz]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Hatch-Waxman]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[M&M]]></category>
		<category><![CDATA[marketsandmarkets]]></category>
		<category><![CDATA[Neupogen]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[QuantiaMD]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[Similar]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Zarxio]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7055</guid>
		<description><![CDATA[On September 3, 2015, in a Press Release, Novartis announced, “Zarxio(TM) (filgrastim-sndz) is now available in the United States. Zarxio is the first biosimilar approved by the US Food and Drug Administration (FDA) and the first to launch in the &#8230; <a href="http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does Patent Expiry Matter Less For Difficult To Copy Drugs?</title>
		<link>http://www.tapanray.in/does-patent-expiry-matter-less-for-difficult-to-copy-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-patent-expiry-matter-less-for-difficult-to-copy-drugs</link>
		<comments>http://www.tapanray.in/does-patent-expiry-matter-less-for-difficult-to-copy-drugs/#comments</comments>
		<pubDate>Mon, 08 Sep 2014 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advair]]></category>
		<category><![CDATA[aerosol]]></category>
		<category><![CDATA[AirFluSal Forspiro]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[COPD]]></category>
		<category><![CDATA[copy]]></category>
		<category><![CDATA[difficult]]></category>
		<category><![CDATA[Diskus]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inhaler]]></category>
		<category><![CDATA[less]]></category>
		<category><![CDATA[matters]]></category>
		<category><![CDATA[NDDS]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[ParaIV]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[Seretide]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[witty]]></category>
		<category><![CDATA[yusuf]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5865</guid>
		<description><![CDATA[“Patent expiry matters much less for difficult to copy drugs”. Not so long ago, this is what many used to believe in the pharma industry. However, looking at the current trend involving the tech savvy generic players, it appears, gone &#8230; <a href="http://www.tapanray.in/does-patent-expiry-matter-less-for-difficult-to-copy-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-patent-expiry-matter-less-for-difficult-to-copy-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
